Correlation between serum HBV RNA and duration of treatment with nucleos（t）ide analogues in patients with chronic hepatitis B

Xueli FAN; Aiqin ZHAN; Yi AN; Liyan TIAN

doi:10.12449/JCH240111

Volume 40 Issue 1

Jan. 2024

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(1): 58-63

PDF( 721 KB)

Correlation between serum HBV RNA and duration of treatment with nucleos（t）ide analogues in patients with chronic hepatitis B

DOI: 10.12449/JCH240111

Xueli FAN¹,
Aiqin ZHAN^{2
,
,
,},
Yi AN³,
Liyan TIAN¹

1.
Shihezi University School of Medicine，Shihezi，Xinjiang 832000，China
2.
Department of Infectious Diseases，The First Affiliated Hospital of Shihezi University School of Medicine，Shihezi，Xinjiang 832000，China
3.
The First Clinical College of China Medical University，Shenyang 110001，China

Research funding:

‍Tianqing Liver Disease Research Foundation of China Hepatitis Prevention and Treatment Foundation (TQGB20170175)

More Information

Corresponding author: ZHAN Aiqin， zhanaiqin@126.com （ORCID： 0000-0002-5436-1974）
Received Date: 2023-02-20
Accepted Date: 2023-04-07
Published Date: 2024-01-23

Abstract

Abstract

‍ Objective To investigate the serum level of HBV RNA in untreated or treatment-experienced patients with chronic hepatitis B （CHB） and the correlation between serum HBV RNA level and the duration of antiviral therapy with nucleos（t）ide analogues （NAs）. Methods A total of 300 patients with CHB who attended Department of Infectious Diseases in The First Affiliated Hospital of Shihezi University School of Medicine from February to July， 2022， were enrolled as subjects. Related clinical data were collected， and according to the duration of antiviral therapy， they were divided into untreated group with 73 patients， treatment duration ≤1 year group with 91 patients， and treatment duration >1 year group with 136 patients. Serum HBV RNA load， HBV DNA load， and HBsAg concentration were measured for all patients. The Mann-Whitney U test was used for comparison of continuous data between two groups， and the Kruskal-Wallis H test was used for comparison between multiple groups， further pairwise comparison using Bonferroni method； the chi-square test was used for comparison of categorical data； a Spearman correlation analysis was used to investigate the degree of correlation between various indicators. Results The positive rate of HBeAg was 18.3%， and among the patients with negative HBV DNA， the patients with positive HBV RNA accounted for 44.1% （86/195）. There was a significant difference in the distribution of the serum levels of HBV RNA， HBV DNA， and HBsAg between the positive HBeAg group and the negative HBeAg group （Z=10.740， 6.300， and 7.280， all P<0.05）. There was a significant difference in the distribution of DNA level between the untreated group and the treatment duration ≤1 year group （P<0.05）； there was a significant difference in the distribution of HBV RNA and HBV DNA levels between the untreated group and the treatment duration >1 year group （P<0.05）； there was a significant difference in the distribution of HBV RNA， HBV DNA， and HBsAg levels between the treatment duration ≤1 year group and the treatment duration >1 year group （P<0.05）. The correlation analysis between the duration of antiviral therapy and the levels of HBV RNA， HBV DNA， and HBsAg showed that the duration of antiviral therapy had an extremely weak negative correlation with the levels of HBV RNA and HBsAg （r=-0.247 and -0.138， both P<0.05） and a strong negative correlation with the level of HBV DNA （r=-0.771， P<0.001）. There was a low degree of correlation between the serum level of HBV RNA and the serum levels of HBV DNA and HBsAg （r=0.360 and 0.442， both P<0.001）. Further stratified analysis showed that in the untreated group， there was a strong positive correlation between HBV RNA and HBV DNA （r=0.752， P<0.001） and a moderate positive correlation between HBV RNA and HBsAg （r=0.559， P<0.001）； in the treatment duration ≤1 year group， there was a low degree of positive correlation between HBV RNA and HBV DNA/HBsAg （r=0.396 and r=0.388， both P<0.001）； in the treatment duration >1 year group， there was a low degree of positive correlation between HBV RNA and HBsAg （r=0.352， P<0.001）. Conclusion Serum HBV RNA is negatively correlated with the duration of treatment with NAs， and the correlation of HBV RNA with HBV DNA and HBsAg gradually decreases with the increase in the duration of treatment. Therefore， it can be used as a supplementary indicator for monitoring the level of virologic response in CHB patients to a certain extent， with a relatively high accuracy in reflecting the level of viral replication in untreated patients.
- Hepatitis B， Chronic,
- Nucleosides,
- Nucleotides

FullText(HTML)

References(24)

References

[1]	Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2019)[J]. J Clin Hepatol, 2019, 35( 12): 2648- 2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35( 12): 2648- 2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[2]	LIU J, LIANG WN, JING WZ, et al. Countdown to 2030: Eliminating hepatitis B disease, China[J]. Bull World Health Organ, 2019, 97( 3): 230- 238. DOI: 10.2471/BLT.18.219469.
[3]	PETERSEN J, THOMPSON AJ, LEVRERO M. Aiming for cure in HBV and HDV infection[J]. J Hepatol, 2016, 65( 4): 835- 848. DOI: 10.1016/j.jhep.2016.05.043.
[4]	TIAN Y, REN F. Advances in the detection and clearance of hepatitis B virus covalently closed circular DNA(cccDNA)[J]. Chin J Microbiol Immunol, 2019, 39( 11): 875- 879. DOI: 10.3760/cma.j.issn.0254-5101.2019.11.011. 田原, 任锋. 乙型肝炎病毒共价闭合环状DNA(cccDNA)检测和清除的研究进展[J]. 中华微生物学和免疫学杂志, 2019, 39( 11): 875- 879. DOI: 10.3760/cma.j.issn.0254-5101.2019.11.011.
[5]	ZAI WJ, CHEN JL, YUAN ZH. Regulatory mechanisms of the transcription and metabolism of hepatitis B virus covalently closed circular DNA and strategies for silencing and elimination[J]. J Clin Hepatol, 2020, 36( 5): 983- 988. DOI: 10.3969/j.issn.1001-5256.2020.05.006. 宰文静, 陈捷亮, 袁正宏. HBV cccDNA转录代谢调控机制及沉默清除策略[J]. 临床肝胆病杂志, 2020, 36( 5): 983- 988. DOI: 10.3969/j.issn.1001-5256.2020.05.006.
[6]	ZHANG Y, ZHAO JM. Clinical application of covalently closed circular DNA detection techniques[J]. J Clin Hepatol, 2019, 35( 10): 2140- 2144. DOI: 10.3969/j.issn.1001-5256.2019.10.002. 张宇, 赵景民. HBV cccDNA检测技术与临床应用[J]. 临床肝胆病杂志, 2019, 35( 10): 2140- 2144. DOI: 10.3969/j.issn.1001-5256.2019.10.002.
[7]	LEVRERO M, TESTONI B, ZOULIM F. HBV cure: Why, how, when?[J]. Curr Opin Virol, 2016, 18: 135- 143. DOI: 10.1016/j.coviro.2016.06.003.
[8]	WANG J, SHEN T, HUANG XB, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound[J]. J Hepatol, 2016, 65( 4): 700- 710. DOI: 10.1016/j.jhep.2016.05.029.
[9]	XIA MY, CHI H, WU YB, et al. Serum hepatitis B virus RNA level is associated with biochemical relapse in patients with chronic hepatitis B infection who discontinue nucleos(t)ide analogue treatment[J]. Aliment Pharmacol Ther, 2021, 54( 5): 709- 714. DOI: 10.1111/apt.16538.
[10]	LU FM, WANG J, CHEN XM, et al. The potential use of serum HBV RNA to guide the functional cure of chronic hepatitis B[J]. Chin J Hepatol, 2017, 25( 2): 105- 110. DOI: 10.3760/cma.j.issn.1007-3418.2017.02.005. 鲁凤民, 王杰, 陈香梅, 等. 乙型肝炎病毒RNA病毒样颗粒的发现及其对抗病毒治疗临床实践的潜在影响[J]. 中华肝脏病杂志, 2017, 25( 2): 105- 110. DOI: 10.3760/cma.j.issn.1007-3418.2017.02.005.
[11]	KÖCK J, THEILMANN L, GALLE P, et al. Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus[J]. Hepatology, 1996, 23( 3): 405- 413. DOI: 10.1002/hep.510230303.
[12]	TAO YC, WANG ML, LIAO J, et al. Dynamics of serum pregenome RNA in chronic hepatitis B patients receiving 96-month nucleos(t)ide analog therapy[J]. Front Med, 2022, 9: 787770. DOI: 10.3389/fmed.2022.787770.
[13]	ZHANG X, AN XC, SHI L, et al. Baseline quantitative HBcAb strongly predicts undetectable HBV DNA and RNA in chronic hepatitis B patients treated with entecavir for 10 years[J]. Sci Rep, 2021, 11( 1): 13389. DOI: 10.1038/s41598-021-92757-0.
[14]	SHEN S, XIE ZL, CAI DW, et al. Biogenesis and molecular characteristics of serum hepatitis B virus RNA[J]. PLoS Pathog, 2020, 16( 10): e1008945. DOI: 10.1371/journal.ppat.1008945.
[15]	PRAKASH K, RYDELL GE, LARSSON SB, et al. High serum levels of pregenomic RNA reflect frequently failing reverse transcription in hepatitis B virus particles[J]. Virol J, 2018, 15( 1): 86. DOI: 10.1186/s12985-018-0994-7.
[16]	TSUKUDA S, WATASHI K. Hepatitis B virus biology and life cycle[J]. Antiviral Res, 2020, 182: 104925. DOI: 10.1016/j.antiviral.2020.104925.
[17]	LI H, XU WT, DENG BC, et al. Research progress of nucleoside(acid) analogues combined with pegylated interferon in functional treatment of chronic hepatitis B[J]. Clin J Med Offic, 2022, 50( 9): 890- 893. DOI: 10.16680/j.1671-3826.2022.09.04. 李卉, 许文涛, 邓宝成, 等. 核苷(酸)类似物联合聚乙二醇干扰素功能性治愈慢性乙型肝炎研究进展[J]. 临床军医杂志, 2022, 50( 9): 890- 893. DOI: 10.16680/j.1671-3826.2022.09.04.
[18]	GIERSCH K, ALLWEISS L, VOLZ T, et al. Serum HBV pgRNA as a clinical marker for cccDNA activity[J]. J Hepatol, 2017, 66( 2): 460- 462. DOI: 10.1016/j.jhep.2016.09.028.
[19]	WANG Y, LIU YN, LIAO H, et al. Serum HBV DNA plus RNA reflecting cccDNA level before and during NAs treatment in HBeAg positive CHB patients[J]. Int J Med Sci, 2022, 19( 5): 858- 866. DOI: 10.7150/ijms.71737.
[20]	PENG YM, YUAN H, ZHOU YF, et al. Serum hepatitis B virus RNA level in chronic hepatitis B with low level of hepatitis B virus DNA and its influential factors[J]. Chin Gen Pract, 2019, 22( 18): 2217- 2222. DOI: 10.12114/j.issn.1007-9572.2019.00.020. 彭亚梦, 袁浩, 周毅峰, 等. 低水平乙型肝炎病毒DNA慢性乙型肝炎患者血清乙型肝炎病毒RNA水平及其影响因素研究[J]. 中国全科医学, 2019, 22( 18): 2217- 2222. DOI: 10.12114/j.issn.1007-9572.2019.00.020.
[21]	WANG CK, LIU SR. Expression level of serum HBV RNA in HBeAg-positive chronic hepatitis B patients at different periods and its value of measurement[J]. J Clin Hepatol, 2021, 37( 12): 2798- 2801. DOI: 10.3969/j.issn.1001-5256.2021.12.014. 王成康, 刘寿荣. 血清HBV RNA在HBeAg阳性慢性乙型肝炎患者不同时期的表达水平及检测价值[J]. 临床肝胆病杂志, 2021, 37( 12): 2798- 2801. DOI: 10.3969/j.issn.1001-5256.2021.12.014.
[22]	LING XZ, WANG RM, SU MH, et al. Clinical significance of dynamic monitoring of serum HBV pgRNA in CHB patients treated with NAs[J]. Chin J Pract Intern Med, 2022, 42( 5): 404- 408. DOI: 10.19538/j.nk2022050112. 零小樟, 王荣明, 苏明华, 等. 慢性乙型肝炎患者核苷酸类似物治疗中动态监测血清乙型肝炎病毒前基因组RNA的临床意义[J]. 中国实用内科杂志, 2022, 42( 5): 404- 408. DOI: 10.19538/j.nk2022050112.
[23]	ZHU Y, LUO YX, GUO FX, et al. Predictive value of serum HBV RNA for therapeutic effect of entecavir in patients with chronic hepatitis B[J]. J South Med Univ, 2022, 42( 8): 1250- 1255. DOI: 10.12122/j.issn.1673-4254.2022.08.19. 朱莹, 罗园香, 郭凤霞, 等. 血清HBV RNA预测恩替卡韦治疗慢性乙型肝炎患者疗效的价值[J]. 南方医科大学学报, 2022, 42( 8): 1250- 1255. DOI: 10.12122/j.issn.1673-4254.2022.08.19.
[24]	JIANG B, DAI QH, LIU YM, et al. Levels of HBV RNA in chronic HBV infected patients during first-line nucleos(t)ide analogues therapy[J]. Infect Agent Cancer, 2022, 17( 1): 61. DOI: 10.1186/s13027-022-00473-9.

Relative Articles

[1]	Rongjiong ZHENG, Xiaobo LU. Low-level viremia in chronic hepatitis B patients treated with first-line treatment with nucleos（t）ide analogues and its treatment strategies[J]. Journal of Clinical Hepatology, 2024, 40(5): 880-883. doi: 10.12449/JCH240506
[2]	Fengming LU, Bo FENG, Sujun ZHENG, Suzhen JIANG, Ruifeng YANG, Junliang FU, Dong JI, Shuangsuo DANG, Xiaobo LU, Hongsong CHEN, Xinyue CHEN, Hong REN, Zhiliang GAO, Yuemin NAN, Xiaoyuan XU, Junqi NIU, Wenhong ZHANG, Hui ZHUANG. Current status of the research on low-level viremia in chronic hepatitis B patients receiving nucleos(t)ide analogues[J]. Journal of Clinical Hepatology, 2021, 37(6): 1268-1274. doi: 10.3969/j.issn.1001-5256.2021.06.007
[3]	Jiang YingYing, Zheng SuJun. Research advances in predictive markers for HBeAg seroconversion in chronic hepatitis B patients treated with nucleos( t) ide analogues[J]. Journal of Clinical Hepatology, 2020, 36(6): 1358-1361. doi: 10.3969/j.issn.1001-5256.2020.06.036
[4]	Zhou YouQian, Li Cui, Yin FengMing, Zhang HaiYan, Ren Bin, Yang Wei. Change in HBsAg quantification after HBV DNA negative conversion in chronic hepatitis B patients treated with nucleos (t) ide analogues[J]. Journal of Clinical Hepatology, 2019, 35(5): 977-981. doi: 10.3969/j.issn.1001-5256.2019.05.009
[5]	Wang LiLi, Liang YueDong. Research advances in influencing factors for the antiviral effect of nucleos (t) ide analogues[J]. Journal of Clinical Hepatology, 2017, 33(7): 1349-1353. doi: 10.3969/j.issn.1001-5256.2017.07.032
[6]	Hu GaoFei, Li XiaoPeng, Wu ZhenPing, Mei Qing, Li Dan, Zhang WenYuan, Yu TingTing, Cheng Na, Zhang LunLi. Clinical features of acute-on-chronic liver failure induced by withdrawal of nucleos (t) ide analogues[J]. Journal of Clinical Hepatology, 2017, 33(7): 1320-1323. doi: 10.3969/j.issn.1001-5256.2017.07.023
[7]	Zhang Ying, Liu Ming, Peng XiaoHua, Sun LinLin, Wang YaoHui, Xie ShiBin. Clinical features of patients developing primary hepatocellular carcinoma during anti-HBV therapy with nucleos (t) ide analogues[J]. Journal of Clinical Hepatology, 2017, 33(4): 679-683. doi: 10.3969/j.issn.1001-5256.2017.04.016
[8]	Chen Lu, Xie Qing. How to evaluate combination therapy using interferon and nucleos(t)ide analogues[J]. Journal of Clinical Hepatology, 2016, 32(11): 2050-2053. doi: 10.3969/j.issn.1001-5256.2016.11.006
[9]	Zhong ChunXiu, Cai ShaoHang, Yin JunHua, Gao YuLin. Impact of nucleos(t)ide analogues on quality of life in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(11): 2080-2083. doi: 10.3969/j.issn.1001-5256.2016.11.013
[10]	Ning Ling, Sun Jian, Chen Nan, Hou JinLin. Renal safety in chronic hepatitis B patients treated with nucleos(t) ide analogues[J]. Journal of Clinical Hepatology, 2016, 32(5): 981-985. doi: 10.3969/j.issn.1001-5256.2016.05.042
[11]	Liu XiaoYan, Chen Jing, Xiao Long, Tong JingJing, Guan ChongDan, Yan LiLong, Su HaiBin. Clinical features of HBV-associated acute-on-chronic liver failure induced by discontinuation of nucleoside analogues[J]. Journal of Clinical Hepatology, 2016, 32(9): 1766-1769. doi: 10.3969/j.issn.1001-5256.2016.09.028
[12]	Chen HeMin, Shao GuoHui. Criteria for withdrawal of nucleos( t) ide analogues and their clinical significance in treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(7): 1283-1286. doi: 10.3969/j.issn.1001-5256.2016.07.013
[13]	Xu Yong, Feng JiHong. Effects of nucleos(t) ide analogues on estimated glomerular filtration rate and serum creatinine level in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(2): 279-283. doi: 10.3969/j.issn.1001-5256.2016.02.016
[14]	Wang Yang, Liu Shuang, Zhou Li, Zheng SuJun, Duan ZhongPing. Research progress in dynamic evolution characteristics of nucleos( t) ide analogue-resistant mutants[J]. Journal of Clinical Hepatology, 2015, 31(4): 614-617. doi: 10.3969/j.issn.1001-5256.2015.04.034
[15]	Yu YiQi, Chen ShaoLong, Zhang WenHong. Research progress in combination therapy with pegylated interferon and nucleos(t)ide analogues in treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(9): 1513-1519. doi: 10.3969/j.issn.1001-5256.2015.09.039
[16]	Fan Xiu, Lin XiaoDong, Cen XiaoHong, Hou YuXiang. Research advances in drug resistance to nucleos( t) ide analogues in treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2015, 31(4): 611-613. doi: 10.3969/j.issn.1001-5256.2015.04.033
[17]	Li Qiang, Zhuo QiBin, Huang YuXian, Li XinYan, Chen Liang. Combination therapy and sequential therapy with interferons and nucleos( t) ide analogues against HBV[J]. Journal of Clinical Hepatology, 2015, 31(4): 495-499. doi: 10.3969/j.issn.1001-5256.2015.04.005
[18]	Yang WeiMin, Xin GuiJie, Li YanYan. Analysis of application of anti-HBV nucleos(t)ide analogues[J]. Journal of Clinical Hepatology, 2014, 30(5): 446-448. doi: 10.3969/j.issn.1001-5256.2014.05.016
[19]	Lin Fei, Yao Bei, Xu Jie, Xu XiaoYuan. Drug resistance mutations related to nucleos(t)ide analogues in Chinese patients with chronic HBV infection: an analysis of 153 cases [J]. Journal of Clinical Hepatology, 2014, 30(3): 269-273. doi: 10.3969/j.issn.1001-5256.2014.03.018
[20]	Ren Shuang, Zhang Hua, Hu XinCai, Liu Ping. Meta-analysis of the clinical efficacy of combination therapy with traditional Chinese medicine and nucleoside analogue antiviral drugs for chronic hepatitis B[J]. Journal of Clinical Hepatology, 2013, 29(4): 264-269+275.

Supplements(0)

Cited By

Cited by

Periodical cited type(3)

1.	张海莹，王震宇，贾玉缘，陈红松，饶慧瑛. 基线血清HBV RNA水平对TDF治疗CHB合并进展期肝纤维化/代偿期肝硬化患者HBeAg血清学转换的预测价值. 中华检验医学杂志. 2025(01): 49-55 .
2.	余文君，余婷婷，李丽华，王红英，普冬，杨永锐. 血清HBsAg、HBV RNA、GGT及GPR联合检测对慢性HBV感染自然史的诊断价值. 昆明医科大学学报. 2024(07): 99-104 .
3.	盛反修，夏金荣，余艳艳. 富马酸替诺福韦二吡呋酯片联合安络化纤丸对慢性乙型肝炎患者的影响. 中国医学创新. 2024(33): 5-9 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (480) PDF downloads(87)

Correlation between serum HBV RNA and duration of treatment with nucleos（t）ide analogues in patients with chronic hepatitis B

DOI: 10.12449/JCH240111

Abstract

References

Relative Articles

Cited by

Periodical cited type(3)

Other cited types(1)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content